Skip to main content
. Author manuscript; available in PMC: 2008 Sep 15.
Published in final edited form as: Biochem Pharmacol. 2007 Jun 17;74(6):851–859. doi: 10.1016/j.bcp.2007.06.017

Table 1.

Effect of silencing of CtBP1 expression on sensitivity of MDR cancer cells to chemotherapeutic drugs.

IC50
Doxorubicin (μM) Vinblastine (nM) Hydroxyurea (μM)
NCI/ADR-RES NT siRNA 17 ± 2 293 ± 15 125 ± 15
CtBP1 siRNA 6.3 ± 0.3* 95 ± 6** 130 ± 9
A2780DX NT siRNA 1.2 ± 0.1 55 ± 2
CtBP1 siRNA 0.3 ± 0.1** 25 ± 5*

IC50 is the concentration of a drug that inhibited 50% cell viability compared to vehicle-treated controls in MTT assay. Results are the mean ± standard error of three separate experiments.

*

p < 0.05 versus NT siRNA treatment;

**

p < 0.01 versus NT siRNA treatment.